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        Chronic myeloid leukemia (CML) is a clonal, 
multistep, multilineage myeloproliferative disor-
der. It is initiated and propagated by a rare pop-
ulation of CML stem cells that have acquired 
a   BCR-ABL   fusion gene (  1, 2  ). The   BCR-ABL   
fusion gene encodes a chimeric oncoprotein that 
displays constitutively elevated tyrosine kinase 
activity that drives CML pathogenesis (  3, 4  ). 
These features deregulate cellular proliferation 
and apoptosis control through eff  ects on multi-
ple intracellular signaling pathways, including the 
Ras, phosphatidylinositol 3-kinase (PI3K), JAK  –
  STAT, and NF-     B pathways (  5, 6  ). Recently, 
imatinib mesylate (IM), which is an inhibitor 
of the BCR-ABL tyrosine kinase (  4  ), has shown 
promise in treating CML patients (  7  –  9  ). How-
ever, early relapses and IM-resistant disease have 
emerged as signifi  cant clinical problems in some 
IM-treated CML patients (  10, 11  ). Relapses are 
frequently associated with mutations in the BCR-
ABL kinase domain (  10, 12, 13  ), accounting for 
60  –  90% of relapses (  11  ). Dasatinib (DS) and ni-
lotinib (NL) are more recently produced small 
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  Chronic myeloid leukemia (CML) represents the fi  rst human malignancy successfully 
treated with a tyrosine kinase inhibitor (TKI; imatinib). However, early relapses and the 
emergence of imatinib-resistant disease are problematic. Evidence suggests that imatinib 
and other inhibitors may not effectively eradicate leukemic stem/progenitor cells, and 
that combination therapy directed to complimentary targets may improve treatment. 
  Abelson helper integration site   1 (  Ahi-1)/AHI-1   is a novel oncogene that is highly de-
regulated in CML stem/progenitor cells where levels of   BCR-ABL   transcripts are also 
elevated. Here, we demonstrate that overexpression of   Ahi-1/AHI-1   in murine and human 
hematopoietic cells confer growth advantages in vitro and induce leukemia in vivo, 
enhancing effects of   BCR-ABL  . Conversely, RNAi-mediated suppression of   AHI-1   in   BCR-
ABL    –  transduced lin       CD34  +   human cord blood cells and primary CML stem/progenitor 
cells reduces their growth autonomy in vitro. Interestingly, coexpression of   Ahi-1   in   BCR-
ABL    –  inducible cells reverses growth defi  ciencies exhibited by   BCR-ABL   down-regulation 
and is associated with sustained phosphorylation of BCR-ABL and enhanced activation of 
JAK2  –  STAT5. Moreover, we identifi  ed an AHI-1  –  BCR-ABL  –  JAK2 interaction complex and 
found that modulation of AHI-1 expression regulates phosphorylation of BCR-ABL and 
JAK2  –  STAT5 in CML cells. Importantly, this complex mediates TKI response/resistance of 
CML stem/progenitor cells. These studies implicate   AHI-1   as a potential therapeutic 
target downstream of BCR-ABL in CML. 
© 2008 Zhou et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the fi  rst six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons
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in vitro. The regulatory role of Ahi-1/AHI-1 in mediating 
BCR-ABL transforming activities can be further explained 
by demonstration of a direct physical interaction between 
AHI-1 and BCR-ABL at endogenous levels in CML cells. 
This is associated with JAK2 and results in modulation of 
sensitivity to TKIs and diff  ering levels of BCR-ABL tyrosine 
phosphorylation and JAK2  –  STAT5 activity in BCR-ABL  +   
CML cells where   Ahi-1/AHI-1   expression is either coexpressed 
or inhibited. 
    RESULTS   
  Overexpression of   Ahi-1   alone can transform IL-3  –
  dependent BaF3 cells in vitro and in vivo, and these effects 
can be enhanced by   BCR-ABL   
  To investigate the transforming potential of   Ahi-1   in he-
matopoietic cells, we cloned full-length   Ahi-1   cDNA into 
a MSCV-internal ribosomal entry site (IRES)-YFP (MIY) 
vector and overexpressed it in an IL-3  –  dependent cell line 
(BaF3). Quantitative real-time RT-PCR analysis (Q-RT-
PCR) showed that   Ahi-1   transcript levels were greatly in-
creased in   Ahi-1    –  transduced BaF3 clonal cell lines compared 
with control cells (Fig. S1 A available at http://www.jem
.org/cgi/content/full/jem.20072316/DC1).   Ahi-1    –  trans-
duced cells have increased proliferative activity in the presence 
of IL-3, and this eff  ect was markedly enhanced when IL-3 
was not added (3  –  4-fold; P   <   0.01; Fig. S1 C).   Ahi-1    –  trans-
duced cells also had greater cell viability in the presence of a 
low concentration of IL-3 (2 ng/ml) compared with control 
cells (twofold; Fig. S1 D). Interestingly, overexpressing both 
  Ahi-1   and   BCR-ABL   in BaF3 cells further enhanced these 
perturbations, compared with cells transduced with either 
  BCR-ABL   or   Ahi-1   alone (1.5  –  3.5-fold in the absence or 
presence of IL-3; P   <   0.05; Fig. S1, C and D). Western blot 
analysis of protein from two individual clonal lines revealed 
that both protein expression and tyrosine kinase activity of 
p210  BCR-ABL   were highly increased in cells cotransduced with 
  Ahi-1   and   BCR-ABL  , compared with   BCR-ABL    –  transduced 
cells (Fig. S1 E). We also detected higher levels of Ahi-1 pro-
tein expression in the same dually transduced cells than in those 
transduced with Ahi-1 alone. More interestingly, endogenous 
Ahi-1 expression is increased in cells transduced with BCR-
ABL alone compared with control cells with expression lev-
els being similar to those detected in Ahi-1  –  transduced BaF3 
cells (Fig. S1 E). 
  To investigate eff  ects of overexpression of   Ahi-1   on the 
ability of transduced cells to induce leukemias in vivo, we 
injected transduced cells into sublethally irradiated NOD/
SCID  –       2 microglobulin (     2m)   /    mice. Strikingly, mice 
injected intravenously with   Ahi-1    –  transduced BaF3 cells had 
a lethal leukemia within 70 d (5   ×   10  6   cells/per mouse;   
Fig. 1 A  ).   Disease latency was shortened to 40 d with   BCR-
ABL    –  transduced cells alone. Leukemogenic activity was further 
increased by introduction of cotransduced   Ahi-1   and   BCR-
ABL   cells, producing a latency of 26 d (P   <   0.05;   Fig. 1 A  ). 
Mice injected with either parental BaF3 cells or vector control 
cells had no evidence of disease after 120 d. Leukemic mice 
molecule inhibitors of the BCR-ABL  –  encoded kinase with 
greater potencies than IM and predicted broader eff  ective-
ness in patients with IM-resistant disease (  14, 15  ). Recent 
studies have indicated that CML stem/progenitor cells in 
chronic phase patients are less responsive to IM and other 
  tyrosine kinase inhibitors (TKIs), and that they are a critical 
target population for IM resistance (  16  –  18  ). In addition, 
CML stem cells are genetically unstable and rapidly generate 
IM-resistant mutants in vitro (  19  ). Thus, it is critical to iden-
tify other therapies targeting CML stem/progenitor cells to 
prevent acquisition of resistance. There is also an emerging 
imperative to develop complementary therapies that target 
downstream molecular events in the CML stem/progenitor 
cells of those patients who fail to achieve lasting remission 
with current treatments. 
    Abelson helper integration site 1   (  Ahi-1  ) is a novel gene that 
was identifi  ed by provirus insertional mutagenesis in v-abl  –
  induced mouse pre  –  B cell lymphoma as a candidate cooperate 
oncogene (  20  ). Mouse   Ahi-1   encodes a unique protein with 
a SH3 domain, multiple SH3 binding sites, and a WD40-re-
peat domain, which are all known to be important mediators 
of protein  –  protein interactions, suggesting that the normal 
Ahi-1 protein has novel signaling activities and that its deregu-
lation could aff  ect specifi  c cellular signaling pathways. Inter-
estingly, the conserved human homologue (  AHI-1)   has an 
additional coiled  –  coil domain in its N-terminal region. In-
volvement of   Ahi-1   in leukemogenesis is suggested by the 
high frequency of   Ahi-1   mutations seen in certain virus-
  induced mouse leukemias and lymphomas (  20, 21  ). We recently 
demonstrated that   Ahi-1/AHI-1   expression is regulated at 
multiple stages of hematopoiesis in a fashion that is highly 
conserved between mice and humans (  22  ).   Ahi-1/AHI-1   is 
expressed at its highest level in the most primitive hematopoietic 
cells and is rapidly down-regulated as cells begin to diff  erenti-
ate. Interestingly, marked deregulation of   AHI-1   expression is 
seen in several human leukemic cell lines (  22, 23  ), particularly 
in a CML cell line (K562) and in Philadelphia chromosome  –
  positive (Ph  +   BCR-ABL  +  ) primary leukemic cells, but not Ph         
cells, especially in highly enriched leukemic stem cells from 
patients with CML. In addition, levels of   BCR-ABL   transcripts 
are highly elevated in the same CML stem cell population 
(  18, 24  ), suggesting that it may be important to cooperative 
activities of AHI-1 and BCR-ABL to generate a permanently 
expanding clone of deregulated stem cells at the early stage of 
leukemia development. 
  In this study, biological and molecular functions of   Ahi-
1/AHI-1   and its cooperative activities with   BCR-ABL   were 
extensively investigated in primitive mouse and human he-
matopoietic cells using several overexpression, suppression, 
and inducible model systems. We found that overexpression of 
  Ahi-1   alone in primitive hematopoietic cells confers a prolif-
erative advantage in vitro and induces a lethal leukemia in vivo; 
these eff  ects are enhanced by   BCR-ABL  . Stable suppression 
of   AHI-1   by small interfering RNA in   BCR-ABL    –  transduced 
primitive human cord blood (CB) cells and primitive leuke-
mic cells from CML patients reduces their growth autonomy JEM VOL. 205, October 27, 2008 
ARTICLE
2659
eff  ects were enhanced in Ahi-1  –   and BCR-ABL  –  cotransduced 
cells (Fig. S2 available at http://www.jem.org/cgi/content/
full/jem.20072316/DC1). Thus, overexpression of   Ahi-1   
alone in IL-3  –  dependent hematopoietic cells has strong trans-
forming activity in vitro and in vivo, and this is additive with 
the eff  ects of   BCR-ABL  . 
  Overexpression of   Ahi-1   alone confers a growth advantage 
on mouse hematopoietic stem/progenitor cells and enhances 
the effects of   BCR-ABL   
  To further investigate the role of   Ahi-1   as a potential cooper-
ating oncogene relevant to   BCR-ABL    –  mediated transforma-
tion in primitive primary hematopoietic cells, we compared 
the biological behavior of primitive mouse hematopoietic 
cells from the BM of 5-FU  –  treated adult C57BL/6 mice 
after transduction with MSCV-Ahi-1-IRES-YFP and MSCV-
BCR-ABL-IRES-GFP retroviruses, alone or in combination. 
Q-RT-PCR analysis of RNA from FACS-purifi  ed primitive 
injected with either   Ahi-1   or   BCR-ABL    –  transduced cells 
developed splenomegaly and hepatomegaly, with 50  –  90% of 
YFP  +  /Ahi-1  +  , GFP  +  /BCR-ABL  +  , or both YFP  +  GFP  +   cells 
detectable in these tissues (  Fig. 1 B  ). As expected, larger spleens 
and livers were observed in mice injected with both   Ahi-1   
and   BCR-ABL    –  transduced cells (  Fig. 1 B   and   Table I  ).   Inter-
estingly, despite the apparently homogeneous pro  –  B cell 
phenotype of BaF3 cells transplanted, the leukemias gener-
ated from   Ahi-1    –  transduced cells revealed multilineage fea-
tures that included the production of Gr-1  +  Mac-1  +   (myeloid), 
Ter119  +   (erythroid), B220  +   (B-lineage), and CD4  +  CD8  +   
(T-lineage;   Fig. 1 C  ), suggesting that overexpression of   Ahi-1   
induces abnormal diff  erentiation (including lineage switching) 
in hematopoietic cells. This was also observed in mice in-
jected with   Ahi-1   and   BCR-ABL   cotransduced cells. In addi-
tion, YFP  +  /Ahi-1  +   or GFP  +  /BCR-ABL  +   cells purifi  ed from 
BM cells of diseased mice showed increased proliferation and 
reduced apoptosis compared with control BaF3 cells; these 
  Figure 1.       Overexpression of   Ahi-1   induces a lethal leukemia in vivo and these effects can be enhanced by cotransduction of   BCR-ABL  .  
(A) Survival curves of NOD/SCID-    2M     /      mice injected with 5   ×   10  6   BaF3 cells transduced with MIY,   Ahi-1 ,  BCR-ABL ,  and  Ahi-1  plus   BCR-ABL . 8  –  10 
mice were used per each group. (B) Spleen (top) and liver (bottom) weight of mice injected with MIY control cells,   Ahi-1  – transduced  cells,   BCR-ABL  –
  transduced cells, and cells cotransduced with   Ahi-1   and   BCR - ABL.   (C) FACS profi  les of YFP  +   BM cells isolated from a representative moribund mouse 
with leukemia, after injection of   Ahi-1   –  transduced cells and showing expression by the YFP  +   cells of Gr-1/Mac-1, B220, CD4/CD8, Ter119, Sac-1, 
and c-kit.     2660 COOPERATION OF AHI-1 AND BCR-ABL IN CML DEVELOPMENT   | Zhou et al. 
Ahi-1    –  transduced Sca-1  +  lin         cells produced a slightly greater 
number of colony-forming cells (CFCs) than MIY-trans-
duced control cells in semisolid cultures in the presence 
of growth factors (GFs), and some of the Ahi-1  +   CFCs 
(    15%) were already GF independent (  Fig. 2, C and D  ). 
After 4 wk in long-term culture-initiating cell (LTC-IC) 
  assays, which are used to measure stem cell activities in vitro, 
the Sca-1  +  lin        Ahi-1  +   cells produced 3-fold more CFCs 
than control cells (P   <   0.01;   Fig. 2 E  ). All of these endpoints 
(proliferative activity, GF dependence, and CFC output in 
LTC-IC assays) are also perturbed by   BCR-ABL   transduc-
tion. In cells cotransduced with   Ahi-1   and   BCR-ABL  , all 
of these eff  ects were further enhanced compared with cells 
transduced with either   BCR-ABL   alone (2  –  4-fold) or   Ahi-1   
alone (3  –  6-fold; P   <   0.01;   Fig. 2  ). Thus, overexpression of 
  Ahi-1   alone deregulates proliferative control of primitive 
mouse hematopoietic cells, and these eff  ects can be enhanced 
by   BCR-ABL  . 
  Suppression or overexpression of   AHI-1   mediates 
transforming activity of K562 CML cells in vitro and in vivo 
  To investigate directly whether deregulated expression of   AHI-1   
contributes to BCR-ABL  –  mediated transformation of human 
CML, knockdown or overexpression of   AHI-1   in K562 cells, 
a cell line derived from a patient with CML and characterized 
by highly increased expression of   AHI-1   (  22  ), was performed, 
with confi  rmed down-regulation of AHI-1 in suppressed cells 
(AHI/sh4) and overexpression of AHI-1 in overexpressed 
cells (P   <   0.01;   Fig. 3 A  ).   Interestingly, suppression of   AHI-1   
expression reduced GF independence in semisolid cultures 
(up to 5-fold; P   <   0.01;   Fig. 3 B  ) compared with cells trans-
duced with control vector (RPG). Colonies formed by   AHI-1    –
  suppressed cells were much smaller than those of control cells 
(  Fig. 3 C  ). Also, the ability to form a clone from a single cell 
was 2-fold less than that of the controls without GFs in liquid 
suspension cultures (P   <   0.05;   Fig. 3 D  ). In contrast, overexpres-
sion of human   AHI-1   by transduction of EF1     -AHI-1-IRES-
YFP lentivirus in K562 cells resulted in sharply increased 
colony-forming ability compared with control cells (1.5  –  2-
fold; P   <   0.05;   Fig. 3, B and C  ). Importantly, restored ex-
pression of AHI-1 both at RNA and protein levels in AHI/sh4 
cells reversed growth defi  ciencies exhibited by suppression of 
  AHI-1   (  Fig. 3, A  –  C  ). 
  To determine if in vitro eff  ects could be replicated in vivo, 
NOD/SCID-     2m   /   mice were injected subcutaneously with 
Sca-1  +  lin        YFP  +   (Ahi-1  +  ), Sca-1  +  lin        GFP  +   (BCR-ABL  +  ), and 
Sca-1  +  lin        YFP  +  GFP  +   (Ahi-1  +  BCR-ABL  +  )  –  transduced BM 
cells showed that   Ahi-1   transcripts were 40-fold higher in 
  Ahi-1    –  transduced cells compared with cells transduced with 
control vector (MIY). Elevated endogenous   Ahi-1   expression 
was also observed in cells transduced with   BCR-ABL   alone 
as compared with control cells (8-fold; P   <   0.01;   Fig. 2 A  ).   5 d 
after transduction, the rate of expansion of the Sca-1  +  lin        YFP  +   
(Ahi-1  +  ) cells in liquid cultures was approximately twofold 
higher than in cultures initiated with control cells (  Fig. 2 B    ). 
  Table I.      Pathological parameters of leukemic mice injected with transduced cells in vivo 
Cells injected Leukemia/mice Disease latency    a    Spleen weight Liver weight
  g   g 
MIY control 0/10 No disease 0.035   ±   0.006 0.5   ±   0.09
Ahi-1 8/8 70   ±   9.5 0.12   ±   0.04 1.1   ±   0.18
BCR-ABL 8/8 41   ±   5.6 0.25   ±   0.05 1.6   ±   0.25
Ahi-1 + BCR-ABL 8/8 26   ±   4 0.41   ±   0.08 2.1   ±   0.3
  a  Time (in days) to death caused by leukemia.
  Figure 2.       Overexpression of   Ahi-1   in Sca-1  +  lin             mouse     stem/
progenitor BM cells perturbs their in vitro proliferative activity 
and enhances the effects of   BCR-ABL      .   (A) The levels of   Ahi-1   tran-
scripts relative to   GAPDH   from  FACS-purifi  ed MIY (Sca-1  + lin      YFP + ),   Ahi-1  
(Sca-1  + lin      YFP + ),   BCR-ABL   (Sca-1 + lin      GFP +  ), and   Ahi-1   plus   BCR-ABL  
(Sca-1  + lin      YFP + GFP +  ) transduced primary mouse BM cells. (B) Growth 
of each FACS-purifi  ed population with GFs. Viable cell numbers were 
determined by hematocytometer counts of trypan blue  –  excluding cells. 
(C) Number of CFC colonies produced in semisolid cultures   ±   GF from 
the same FACS-purifi  ed mouse BM cells. (D) The appearance of GF-inde-
pendent CFC colonies is shown. Bar, 250   μ  m. (E) The numbers of LTC-IC  –
  derived CFCs produced from the same cells   ±   GF. Values shown are the 
mean   ±   SEM of triplicate measurements. * indicates signifi  cantly differ-
ent from MIY control cells.     JEM VOL. 205, October 27, 2008 
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  Suppression of   AHI-1   expression in primitive   BCR-ABL    –
  transduced human CB cells and primary CML stem/
progenitor cells reduces their growth autonomy 
  We next evaluated the eff  ects of down-regulation of   AHI-1   in 
  BCR-ABL    –  transduced primitive human CB stem/progenitor 
cells (Lin        CD34  +  ) using lentiviral-mediated RNA interfer-
ence. Q-RT-PCR analysis indicated that endogenous   AHI-1   
expression was suppressed by 40  –  50% when the shRNA con-
struct (AHI/sh4) was introduced (  Fig. 4 A  ).   Interestingly, 
  BCR-ABL    –  transduced CB cells expanded rapidly in the pres-
ence or absence of GFs as expected, but the growth of the 
transduced cells to determine their ability to form tumors in 
vivo. Cells with suppression of   AHI-1   failed or had signifi  -
cantly reduced ability to form tumors compared with control 
K562 cells (  Fig. 3, E and F  ). In contrast,   AHI-1   overexpressed 
cells rapidly generated larger tumors than the control cells 
within 3 wk (3-fold; P   <   0.01). Strikingly, AHI/sh4 cells co-
transduced with the AHI-1 construct could reverse in vivo 
growth defi  ciencies resulting from knockdown of   AHI-1  . 
These results demonstrate that modulation of expression levels 
of   AHI-1   in human CML cells regulates their transforming ac-
tivity in vitro and in vivo. 
  Figure 3.       Knockdown or overexpression of   AHI-1   in human K562 cells mediates their transforming activity in vitro and in vivo.   (A)  Q-RT-PCR 
analysis of the levels of   AHI-1   transcripts relative to   GAPDH   in  FACS-purifi  ed RPG vector  –  transduced K562 cells, AHI-1/sh4 cells (with suppression of 
  AHI-1  ), AHI/sh4 + AHI-1 cells (coexpression of   AHI-1   in AHI-1/sh4 cells), and AHI-1 cells (  AHI-  1 overexpressed cells, top). Western analysis (bottom) of 
AHI-1 expression in the same transduced cells with an anti  –  AHI-1 antibody. (B) The numbers of CFC colonies produced in semisolid cultures   ±   GF (IL-3, 
GM-CSF, SF) in the same transduced cells. (C) The appearance of CFC colonies produced in semisolid cultures   ±   GF as shown in B. Bar, 250   μ  m. (D) Per-
centage of single control K562 cells or AHI/sh4 cells generating clones (top) and clone size distributions obtained from these cells after being cultured for 
7 d (bottom). (E) NOD/SCID-    2M     /      mice were injected subcutaneously with 10  7   control K562 and transduced cells. Tumor volume is expressed as mean   ±   
SEM areas of each group (  n   = 4). (F) The appearance of tumors generated by the same cells as shown in E. Values shown are the mean   ±   SEM of triplicate 
measurements. * indicates signifi  cantly different from K562 or RPG control cells.     2662 COOPERATION OF AHI-1 AND BCR-ABL IN CML DEVELOPMENT   | Zhou et al. 
Interestingly, lin        CD34  +   cells from IM nonresponders expressed 
higher levels of   AHI-1   transcripts compared with the same cells 
isolated from IM responders (P = 0.03;   Fig. 5 A  ). Lin        CD34  +   
cells from blast crisis patients also expressed relatively higher levels 
of   AHI-1   transcripts (P   <   0.03, compared with IM responders). A 
lentiviral-mediated   AHI-1   shRNA construct was directly trans-
duced into lin        CD34  +   stem/progenitor cells isolated from three 
IM responders, three IM nonresponders, and three blast crisis 
patients. Lentiviral-mediated suppression of   AHI-1   expression re-
sulted in a reduction in CFC output by     28  –  60% in lin        CD34  +   
CML cells from all patient samples studied (with  AHI-1   expression 
partially suppressed (    40  –  55%;   Fig. 5, B and C  ). CFC colonies 
formed by CML cells with suppression of   AHI-1   were found to 
be smaller than those resulting from cells transduced with a control 
vector ( Fig. 5 D ). It was interesting that more signifi  cant reduction 
  BCR-ABL    –  transduced cells with suppression of   AHI-1   was sig-
nifi  cantly suppressed (2.2   ×   10  6   versus 4.8   ×   10  5   cells with GF; 
10  6   versus 5   ×   10  3   cells without GF; P   <   0.01;   n   = 3;   Fig. 4 B  ). 
Similarly,   BCR-ABL    –  transduced CB cells with suppression of 
  AHI-1   had up to 10-fold less CFC output compared with 
  BCR-ABL    –  transduced CB cells (P   <   0.01;   Fig. 4 C  ). A similar 
reduction of CFC output was observed in the absence of GFs 
(data not shown). Notably, burst-forming-units-erythroids 
(BFU-Es) were especially increased in   BCR-ABL    –  transduced 
CB cells compared with control cells, which remained pre-
dominantly myeloid as previously reported (110   ±   8 versus 
18   ±   3; P   <   0.01;   Fig. 4 C  ) (  25  ). Suppression of   AHI-1   expression 
in   BCR-ABL  -transduced CB cells signifi  cantly reduced mye-
loid CFC (BFU-E and colony-forming units-granulocyte-
macrophage [CFU-GM]) output, as well as primitive myeloid 
progenitors (colony-forming units-granulocyte-erythrocite-
monocyte-megakaryocyte [CFU-GEMM]), suggesting that 
AHI-1 may play a role in regulation of overproduction of mye-
loid cells in CML. 
  To further elucidate the role of   AHI-1   in primary CML stem/
progenitor cells,   AHI-1   transcript levels were evaluated in pre-
treatment lin        CD34  +   cells from 16 chronic phase patients with 
subsequent clinical responses to IM therapy (6 responders and 10 
nonresponders) and from 7 patients in blast crisis. Increased levels 
of   AHI-1   expression were observed in lin        CD34  +   CML stem/
progenitor cells from all patient samples studies (2.5  –  18-fold; 
P   <   0.04;   Fig. 5 A  ), compared with lin        CD34  +   normal BM cells.   
  Figure 4.       Lentiviral-mediated suppression of   AHI-1   expression 
causes reduced proliferative activity and GF independence of   BCR-
ABL    –  transduced human CB cells.   (A) Q-RT-PCR analysis of the levels 
of human   AHI-1   transcripts relative to   GAPDH   in transduced lin       CD34 +  
CB cells, including cells transduced with a control vector (Ctrl), AHI/sh4 
cells (with suppression of   AHI-1 ),   BCR-ABL   (B/A), and AHI/sh4 cotrans-
duced cells (B/A + AHI/sh4). (B) Growth of each transduced population 
in suspension cultures   ±   GF for 12 d. Viable cell numbers were deter-
mined by hematocytometer counts of trypan blue-excluding cells. 
(C) Number of BFU-E, CFU-GM, and CFU-GEMM colonies produced in 
semisolid cultures from the same cells as shown in B. Values shown are 
the mean   ±   SEM of triplicate measurements. * indicates signifi  cant dif-
ference between   BCR-ABL    –  transduced cells alone and cells cotrans-
duced with   BCR-ABL   and  AHI/sh4.   
  Figure 5.       Elevated   AHI-1   transcript levels in CML stem/progenitor 
cells and reduced CFC production in the same cells when   AHI-1   
expression is suppressed.   (A) Q-RT-PCR analysis of the levels of human 
  AHI-1   transcripts relative to   GAPDH   in  lin      CD34 +   normal bone marrow 
(NBM) and lin       CD34 +   CML cells from IM responders, nonresponders, and 
blast crisis patients. (B) Q-RT-PCR analysis of the levels of human   AHI-1  
transcripts relative to   GAPDH   in transduced lin       CD34 +   normal BM and 
CML cells (three IM responders, three nonresponders, and three blast crisis 
patients)   ±   suppression of   AHI-1   expression, including cells transduced 
with a control vector (Ctrl) or a AHI/sh4 vector. (C) The yield of BFU-E, 
CFU-GM, and CFU-GEMM colonies from primary CD34  + lin        CML  cells 
transduced with a control vector or AHI/sh4 vector. (D) The appearance of 
CFC colonies produced in semisolid cultures from control and AHI/sh4-
transduced cells from an IM nonresponder patient. Bar, 100   μ  m. Values 
shown are the mean   ±   SEM of triplicate measurements. * indicates sig-
nifi  cant difference between transduced control cells and cells transduced 
with AHI/sh4 vector.     JEM VOL. 205, October 27, 2008 
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cooperative eff  ects of   Ahi-1   in a   BCR-ABL    –  transduced BaF3 
cell line in which the level of expression of p210  BCR-ABL   can 
be variably down-regulated by exposure to doxycycline (Dox) 
(  26  ). Reduction in BCR-ABL protein expression in the pres-
ence of Dox results in a corresponding decrease in GF inde-
pendence of BaF3 cells both in liquid suspension cultures 
and in semisolid cultures in vitro (  Fig. 6  ).   As shown in   Fig. 6 
(A and B)  , cell growth and survival was dramatically reduced 
in CFC numbers was observed in transduced primary CML cells 
from IM nonresponders and blast crisis compared with IM re-
sponders (  Fig. 5 C  ). 
  Coexpression of   Ahi-1   in   BCR-ABL    –  inducible cells regulates 
transforming activities of   BCR-ABL    +   cells 
  To further investigate potential regulatory roles of   Ahi-1   in 
mediating   BCR-ABL    –  transforming activities, we evaluated 
  Figure 6.       Overexpression of   Ahi-1   rescues growth suppression induced by the inhibition of   BCR-ABL   expression in BCR-ABL  –  inducible BaF3 
cells.   (A) Growth of control BaF3,   BCR-ABL  –  inducible cells, and two   Ahi-1  – transduced,   BCR-ABL    –  inducible clonal lines without IL-3   ±   Dox (+Dox = sup-
pression of   BCR-ABL   expression). Viable cell numbers were determined by hematocytometer counts of trypan blue  –  excluding cells. (B) Annexin V-PE/7-
AAD staining of   BCR-ABL   –  inducible cells and   Ahi-1  – transduced   BCR-ABL   –  inducible cells (Ahi-1 + B/A-2) after culture without IL-3   ±   Dox for 24 and 48 h. 
Percentages of Annexin V  +   cells are indicated. (C) CFC colonies produced in semisolid media   ±   IL-3 and Dox from the same cells as shown in A. (D) The 
appearance of GF-independent CFC colonies in   Ahi-1   and   BCR-ABL    –  cotransduced cells without IL-3   ±   Dox. Bar, 250   μ  m. Values shown are the mean   ±   
SEM of triplicate measurements. * indicates signifi  cant difference between   BCR-ABL   inducible cells alone and inducible cells cotransduced with   Ahi-1 .   2664 COOPERATION OF AHI-1 AND BCR-ABL IN CML DEVELOPMENT   | Zhou et al. 
caused by suppression of   BCR-ABL   expression. This can be 
enhanced signifi  cantly by cotransduction of   Ahi-1   (10  –  15-
fold; P   <   0.01;   Fig. 6 C  ). Collectively, these results demon-
strate the ability of   Ahi-1   to immediately reverse in vitro 
growth defi  ciencies resulting from down-regulation of   BCR-
ABL   in vitro, and provide direct evidence of the regulatory 
role of   Ahi-1   in   BCR-ABL    –  mediated transformation. 
  Coexpression of   Ahi-1   in   BCR-ABL    –  inducible cells sustains 
tyrosine phosphorylation of BCR-ABL and enhances 
activation of JAK2 and STAT5 
  To determine whether coexpression of   Ahi-1   in   BCR-ABL    –
  inducible BaF3 cells infl  uences protein expression and tyro-
sine kinase activity of BCR-ABL, and candidate downstream 
signaling that refl  ects enhanced transforming phenotypes ob-
served, we performed Q-RT-PCR and Western blot anal-
yses in these cells in the presence and absence of Dox. As 
expected,   BCR-ABL   transcripts were highly expressed with-
out Dox and down-regulated in the presence of Dox in the 
  BCR-ABL    –  inducible cells after 24  –  48 h in culture (  Fig. 7 A  ).   
Elevated   BCR-ABL   transcript levels were again observed in 
  BCR-ABL  –     and  Ahi-1    –  cotransduced cells generated from two 
individual cells lines (3  –  6-fold; P   <   0.01). As expected,   Ahi-1   
transcripts were highly elevated in cotransduced cells when 
compared with control BaF3 cells (  >  50-fold; P   <   0.01;   Fig. 
7 A  ). Strikingly, tyrosine phosphorylation of p210  BCR-ABL   could 
not sufficiently be suppressed in   Ahi-1  - and   BCR-ABL    – 
cotransduced cells, as compared with   BCR-ABL    –  transduced 
cells alone in the presence of the same amount of Dox (30  –
  40% inhibition versus     80% inhibition; P   <   0.01;   Fig. 7, 
B and C  ). In all cases, BCR-ABL phosphorylation was not 
completely suppressed after 24 h in culture with addition of 
Dox. These results were consistently observed in two individ-
ual cotransduced cell lines. Similarly, BCR-ABL protein ex-
pression was also suppressed to a lesser degree in cotransduced 
cells than in cells transduced with   BCR-ABL   only, and Ahi-1 
protein expression was found to be higher in cotransduced 
cells than in cells transduced with   BCR-ABL   only. 
  We next evaluated the eff  ect of increased BCR-ABL ex-
pression and tyrosine phosphorylation of cotransduced cells 
on the activity of candidate signaling mechanisms. We ob-
served increased levels of phosphorylation of JAK2, STAT5, 
NF-     B p65 (at Ser 563 and Ser 468), and Src (at Tyr 416) in 
  BCR-ABL    –  inducible cells and   Ahi-1    –  cotransduced   BCR-
ABL    –  inducible cells compared with control BaF3 cells (  Fig. 
8, A and B  ).   Interestingly, phosphorylation of most down-
stream proteins was down-regulated when BCR-ABL ex-
pression was inhibited by Dox, but sustained phosphorylation 
of JAK2 and STAT5 was consistently observed in cotrans-
duced cells in the presence of IL-3 and Dox (  Fig. 8 A  , lanes 
6 and 8 compared with lane 4). In the absence of IL-3, phos-
phorylation of JAK2 and STAT5 was reduced in cotrans-
duced cells when BCR-ABL expression was suppressed. A 
similar, albeit less pronounced, fi  nding of sustained phosphory-
lation of Src was also observed, particularly in Ahi-1 + BCR-
ABL-1 cells in the presence of IL-3. These results suggest 
when Dox was added to culture at 48 h (  >  90% inhibition 
of proliferation,   Fig. 6 A,   right;     50% detectable Annexin V  +   
apoptotic cells,   Fig. 6 B,   top right), while the same cells 
showed a marked increase in cell expansion in the absence 
of both IL-3 and Dox (no down-regulation of BCR-ABL, 
  Fig. 6 A  , left). Similarly, down-regulation of   BCR-ABL   ex-
pression completely inhibited CFC generation in semisolid 
cultures in the absence of IL-3 (  Fig. 6, C and D  ). Interest-
ingly, introduction of   Ahi-1   into cells with inhibited   BCR-
ABL   expression under these stringent conditions enabled them 
to grow continuously in liquid suspension culture, to have 
less Annexin V  +   apoptotic cells, and to produce more factor-
independent CFCs than cells transduced with   BCR-ABL   
alone (    4   ×   10  5   versus 10  3   cells after 48 h in liquid culture 
and     100 CFCs versus 0 in the CFC assay; P   <   0.01;   Fig. 6  ). 
These results were consistently observed in two individual clonal 
cell lines. In the presence of IL-3 and Dox,   BCR-ABL    –  trans-
duced BaF3 cells showed a signifi  cant reduction in CFC pro-
duction; addition of IL-3 cannot rescue inhibitory effects 
  Figure 7.       Sustained tyrosine phosphorylation and protein expres-
sion of P210  BCR-ABL   in   BCR-ABL    –  inducible BaF3 cells cotransduced 
with   Ahi-1  .   (A) Q-RT-PCR analysis of the levels of   BCR-ABL   (left) and 
  Ahi-1   (right) transcripts relative to   GAPDH   in control BaF3,   BCR-ABL   in-
ducible cells and two   Ahi-1- transduced   BCR-ABL   inducible clonal lines 
cultured without IL-3   ±   Dox for 24 h. (B) Western analyses of cell lysates 
from the same cells for 24 h. Antibodies used are indicated. (C) Tyrosine 
phosphorylation and protein expression of p210  BCR-ABL   and Ahi-1 relative 
to actin, as compared with   BCR-ABL  – transduced  cells  alone.  Values 
shown are the mean   ±   SEM of triplicate measurements. * indicates sig-
nifi  cant difference between   BCR-ABL    –  inducible cells alone and the induc-
ible cells cotransduced with   Ahi-1 .   JEM VOL. 205, October 27, 2008 
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lated p210  BCR-ABL   could be detected in K562 cells using an 
antiphosphotyrosine antibody (4G10) after IP with the AHI-1 
antibody (  Fig. 8 E  ). Interestingly, this protein interaction 
complex is also associated with a 120-kD tyrosine-phosphor-
ylated protein (  Fig. 8 E  ). To determine whether this 120-kD 
protein could be an AHI-1 isoform, the same membrane was 
washed and reprobed with an AHI-1 antibody. The full-length 
(150 kD) and a 100-kD isoform of AHI-1 protein (but not 
a 120-kD protein) were identifi  ed by Western blot analyses 
(  Fig. 8 F  ). Using co-IP, we examined several candidate 120-kD 
tyrosine-phosphorylated proteins known to interact with BCR-
ABL, including CBL and JAK2. We determined that JAK2 
was associated with this protein interaction complex, as AHI-1 
could be detected by an anti  –  AHI-1 antibody in K562 cells 
after IP with a specifi  c antibody to JAK2 (  Fig. 8 G  ); this in-
teraction was further confi  rmed by reverse detection of JAK2 
after IP with the anti-AHI-1 antibody (not depicted). In ad-
dition, the antigenic peptide derived from the sequence of 
AHI-1 specifi  cally blocked the ability of the AHI-1 antibody 
to precipitate both tyrosine-phosphorylated BCR-ABL and 
the 120-kD protein, whereas an unrelated peptide had no 
eff  ect (  Fig. 8 H  , lane 3). Interestingly, this interaction com-
plex was found to be modulated by tyrosine kinase activity 
of BCR-ABL, as IM treatment (5   μ  M) of K562 cells for 6 h 
resulted in inability to detect both tyrosine-phosphorylated 
BCR-ABL and JAK2 (  Fig. 8 H  , lane 4). These results indicate 
that AHI-1 and BCR-ABL can interact and form a complex 
involving tyrosine-phosphorylated JAK2. 
  AHI-1 regulates response of BCR-ABL  +   primitive CML 
cells to TKIs 
  To determine whether AHI-1  –  BCR-ABL  –  JAK2 interaction 
complex may mediate IM sensitivity/resistance of BCR-
ABL  +   cells,   BCR-ABL    –  transduced inducible BaF3 cells and 
cells cotransduced with   Ahi-1   were treated with various doses 
of IM (0  –  10   μ  m). As expected,   BCR-ABL    –  transduced cells 
showed a signifi  cant reduction in CFC output in response to IM 
treatment in the presence and absence of IL-3 (    90% inhibition 
with 5   μ  M IM + IL-3 and 1   μ  M IM   IL-3;   Fig. 9 A  ).   Strik-
ingly, BaF3 cells cotransduced with   Ahi-1   and   BCR-ABL   
showed no response to IM and produced as many CFCs in 
the presence of IL-3 as were produced by the same cells with-
out IM treatment (  Fig. 9 A  , left). Moreover, cotransduced 
cells also displayed greater resistance to IM in CFC output in 
the absence of IL-3, although these cells were more sensitive 
to IM treatment than those in the presence of IL-3 (  Fig. 9 A  , 
right). These results indicate that   Ahi-1   is capable of over-
coming IM-induced growth suppression in BCR-ABL  +   cells 
when IL-3 signaling is activated in these cells. 
  Similarly, overexpression of human   AHI-1   in K562 cells 
resulted in greater resistance to IM treatment, as assessed by 
the CFC assay, (    2-fold; P   <   0.01) in comparison to K562 
control cells (  Fig. 9 C  ). Conversely, suppression of   AHI-1   
(AHI/sh4) resulted in increased sensitivity to IM, particularly 
in the presence of a low concentration of IM (1   μ  M). Strik-
ingly, restored expression of   AHI-1   by overexpression of an 
that Ahi-1 may play a regulatory role in mediation of BCR-
ABL activity associated with enhanced activation of JAK2 and 
STAT5 through the IL-3 signaling pathway. 
  AHI-1 physically interacts with BCR-ABL 
  To detect a physical interaction between AHI-1 and BCR-
ABL in CML cells, coimmunoprecipitation (co-IP) experi-
ments were performed. We demonstrated a direct interaction 
between AHI-1 and BCR-ABL at endogenous levels by 
detection of BCR-ABL in human CML cells (K562) after 
IP with a human AHI-1 antibody (  Fig. 8 C  ). This interac-
tion was not found in a BCR-ABL         T cell line (Hut 78;   Fig. 
8 C  , lane 2) or in control antibody coimmunoprecipitated 
K562 cells (not depicted). The result was confi  rmed by de-
tection of AHI-1 in the same cells after IP with a specifi  c 
antibody to ABL (  Fig. 8 D  ). Importantly, tyrosine phosphory-
  Figure 8.       Enhanced activation of JAK2 and STAT5 in   BCR-ABL   
inducible BaF3 cells cotransduced with   Ahi-1   and detection of a 
AHI-1  –  BCR-ABL  –  JAK2 interaction complex in human K562 cells.  
(A and B) Western blot analyses of cell lysates from control BaF3, BCR-
ABL  –  inducible cells, and two   Ahi-1  – transduced   BCR-ABL  – inducible  clonal 
lines cultured in the presence (A) and absence (B) of IL-3   ±   Dox for 24 h. 
Antibodies used are indicated. (C  –  H) Protein lysates of K562 cells (BCR-
ABL  +  ) and Hut 78 cells (BCR-ABL        ) were used to immunoprecipitate AHI-
1 (C, E-F, and H), ABL (D), and JAK2 (G), and proteins were detected by 
Western blotting with antibodies to ABL (C), AHI-1 (D, F, and G), JAK-2 (G), 
and phosphotyrosine (E and H) as indicated. In H, before immunoprecipi-
tation, lysates were incubated for 1 h with the indicated AHI-1 peptide; 
unrelated peptide (unr.), no peptide (-), and antigenic peptide (+) or cells 
were incubated   ±   IM (5   μ  M) for 6 h before preparation of protein lysates.     2666 COOPERATION OF AHI-1 AND BCR-ABL IN CML DEVELOPMENT   | Zhou et al. 
  expression of AHI-1 not only modulates phosphorylation of 
BCR-ABL, JAK2, and STAT5 in BCR-ABL  +   K562 cells, 
but also regulates protein expression of these genes, as dem-
onstrated by signifi  cantly enhanced expression of these pro-
teins when   AHI-1   is overexpressed, reduced expression when 
  AHI-1   is suppressed, and restored expression in AHI-1  –  sup-
pressed cells where   AHI-1   expression has been rescued by 
introduction of an AHI-1 construct (  Fig. 9 D  ). These results 
further support our fi  ndings in the BCR-ABL  –  inducible sys-
tem that AHI-1 plays a critical role in mediation of BCR-
ABL and JAK2  –  STAT5 activities. 
  We next assessed sensitivity of lin        CD34  +   CML stem/
progenitor cells, with and without suppression of   AHI-1   ex-
pression, to the TKIs IM, DS, and NL. Cells were obtained 
from three IM responders, three IM nonresponders, and 
three blast crisis patients with partial suppression of   AHI-1   
expression in transduced CML cells (    40  –  50%) as shown in 
  Fig. 5 B  . Interestingly, in all cases, lin        CD34  +   CML cells 
were more sensitive to DS treatment (100 nM) than to IM 
(5   μ  M) or NL (5   μ  M), as assessed by their ability to generate 
CFCs (  Fig. 9 E  ), whereas lin        CD34  +   cells with suppression 
of   AHI-1   expression, particularly cells from the clinically IM-
resistant and blast crisis patients, were more sensitive to all 
three inhibitors (    2-fold; P   <   0.05). Collectively, these data 
suggest that   AHI-1   plays an important role in modulating sen-
sitivity to IM and other selective BCR-ABL TKIs in   BCR-
ABL  +     CML cells. 
    DISCUSSION   
  In this study, we demonstrate for the fi  rst time that   Ahi-1/
AHI-1   is a new oncogene that cooperates in transforming ac-
tivities with   BCR-ABL   both in vitro and in vivo through a 
direct physical interaction. First, in a mouse system, overex-
pression of mouse   Ahi-1   confers a proliferative advantage in 
vitro to IL-3  –  dependent BaF3 cells and a stem cell  –  enriched 
Sca-1  +  lin         population from 5-FU  –  treated mouse BM cells, 
and induces a lethal leukemia in vivo. This deregulated pro-
liferative activity, GF independence, and leukemogenic po-
tential is enhanced by introduction of   BCR-ABL  . Thus, there 
is a direct biological correlation between   Ahi-1   and   BCR-
ABL   in regulating transforming activity of these cells. Sec-
ond, in a human system,   AHI-1   expression appears to regulate 
transforming activities of   BCR-ABL    –  transduced human CB 
stem/progenitor cells (lin        CD34  +  ), as indicated by their sig-
nifi   cantly reduced autonomous growth when endogenous 
  AHI-1   expression is stably inhibited. These eff  ects were fur-
ther demonstrated in CML patient samples; reduced autono-
mous growth was observed in primary CML stem/progenitor 
cells in all patient samples studied with knockdown of   AHI-1  . 
The eff  ects were more signifi  cant in CML stem/progenitor 
cells from IM-resistant patients and blast crisis patients who 
expressed relatively higher levels of   AHI-1   (  Fig. 5  ). Knock-
down of   AHI-1   expression in   BCR-ABL    –  transduced human 
CB cells not only inhibited all diff  erentiated myeloid cells 
(CFU-GM and CFU-GEMM) but also signifi  cantly inhib-
ited diff  erentiating erythroid cells (BFU-E;   Fig. 4 C  ) that are 
AHI-1 construct in AHI/sh4 cells (suppression of   AHI-1  ) 
  restored IM resistance to AHI/sh4 cells (  Fig. 9 C  ). Western 
analysis revealed increased tyrosine-phosphorylated BCR-
ABL, JAK2, and STAT5 in K562 cells with   AHI-1   overex-
pression and reduced levels of these phosphorylated proteins 
when   AHI-1   expression is suppressed (  Fig. 9 D  ). Interest-
ingly, phosphorylated BCR-ABL, JAK2, and STAT5 levels 
could be restored in the AHI-1/sh4 cells when AHI-1 con-
struct was reintroduced into the same cells. Importantly, 
  Figure 9.         AHI-1   mediates response/resistance of TKIs as assessed 
by overexpression or suppression of   AHI-1   in   BCR-ABL  +     primitive 
CML cells.   (A) Percentage of inhibition of CFC colonies generated in 
semisolid media   ±   IL-3 and IM (0  –  5   μ  M) from control BaF3,   BCR-ABL  –
  inducible cells, and two   Ahi-1 –  transduced   BCR-ABL  – inducible  clonal 
cell lines. (B) Model of AHI-1  –  BCR-ABL  –  JAK2 complex regulation of 
constitutive activation of BCR-ABL and JAK2  –  STAT5 pathway, resulting 
in increased proliferation and reduced TKI response of CML stem/pro-
genitor cells. (C) Percentage of inhibition of CFC generation in semisolid 
media with GF and IM (0  –  10   μ  M) from control K562, AHI/sh4  –  trans-
duced cells (suppression of   AHI-1 ), overexpression of   AHI-1  in AHI/sh4 
cells, and   AHI-1   –  transduced K562 cells. * indicates signifi  cantly different 
from K562 control cells. (D) Western analyses of cell lysates from the 
same cells   ±   IM (5   μ  M) for 6 h. Antibodies used are indicated. 
(E) Inhibition of CFCs in semisolid media with IM (5   μ  M), DS (100 nM), 
and NL (5   μ  M) in lin       CD34 +   CML cells from IM responders (  n   = 3), non-
responders (  n   = 3), and blast crisis (  n   = 3) patient samples transduced 
with either a control vector or AHI-1/sh4 vector. Values shown are the 
mean   ±   SEM of triplicate measurements. * indicates signifi  cantly differ-
ent between   BCR-ABL    –  inducible cells and inducible cells cotransduced 
with   Ahi-1  , and between lin       CD34 +   cells transduced with a control 
vector or transduced with the AHI-1/sh4 vector.     JEM VOL. 205, October 27, 2008 
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ABL and JAK2  –  STAT5 (  Fig. 9 D  ). It is known that BCR-
ABL signaling closely mimics signaling pathways of cytokine 
receptors and that both IL-3/GM-CSF receptor activation and 
the BCR-ABL oncoprotein can induce a tyrosine phosphory-
lation cascade of which numerous proteins, including JAK2 
and STAT5, are common substrates (  5, 6, 31  ). Interestingly, 
  BCR-ABL    –  expressing cells have many similarities to cells in-
duced by IL-3 stimulation (  32  ) or cells with forced   IL-3   over-
expression (  33, 34  ). Early studies have shown that BCR-ABL 
can interact with the common       chain of IL-3/GM-CSF 
  receptor and constitutively activate JAK2 (  35  ). In particular, 
increased phosphorylation of STAT5, which was previously 
thought to be an immediate function of the BCR-ABL on-
coprotein, has now been shown in primary CML CD34  +   
progenitor cells to occur largely as a consequence of BCR-
ABL  –  induced activation of IL-3 autostimulation, leading to 
activation of STAT5 (  36  ). It has been reported that targeted 
disruption of the   STAT5A   and   STAT5B   genes reduces mye-
loid progenitor numbers, suggesting a nonredundant role for 
STAT5 in primitive normal hematopoiesis (  37  ). Recent studies 
further suggest that autocrine production of GM-CSF may 
contribute to IM and NL-resistance in BCR-ABL  +   progeni-
tors through activation of JAK2 and STAT5 pathway (  38  ), 
and inhibition of   STAT5   expression by a shRNA approach 
signifi  cantly reduced colony formation of CD34  +   CML pro-
genitor cells in vitro (  39  ). In addition, JAK2 is known to interact 
with the C-terminal region of BCR-ABL, and recent studies 
further show that mouse hematopoietic cells transformed by 
the T315I mutant of   BCR-ABL   can be induced to undergo 
apoptosis by a JAK2 inhibitor (AG490) (  40  –  42  ). Collectively, 
these results indicate that activation of the JAK2  –  STAT5 
pathway in CML stem/progenitors is likely to be an impor-
tant mechanism contributing to responses to BCR-ABL  –  tar-
geted therapies and identifi  cation of Ahi-1/AHI-1 as a novel 
mediator involved in this pathway suggests AHI-1 alone or in 
combination with JAK2 and STAT5, as potential additional 
therapeutic targets. 
  The most revealing result presented here is the fi  nding that 
expression of   BCR-ABL   was consistently associated with an 
up-regulation of endogenous   Ahi-1/AHI-1   transcripts and an 
increase in Ahi-1/AHI-1 protein expression in several over-
expression and inducible experimental systems. Up-regulated 
  AHI-1   expression has been noted in K562 cells, a cell line de-
rived from a patient with CML in blast crisis (  22  ). In particu-
lar, modulation of   AHI-1   expression in K562 cells regulates 
BCR-ABL and JAK2  –  STAT5 activities, as described above. 
Importantly,   AHI-1   is highly deregulated in primary CML 
stem/progenitor cells where levels of   BCR-ABL   transcripts 
are also highly elevated, suggesting that deregulated expression 
of   BCR-ABL   and   AHI-1   may be clinically relevant to their 
cooperative activities that result in a permanently expanding 
clone of deregulated stem cells during leukemia development. 
Indeed, our study further demonstrates that highly elevated 
levels of   AHI-1   in CML stem/progenitor cells from IM non-
responders and blast crisis patients correlate with their rela-
tive resistance to TKIs. Similarly, a potential mechanism for a 
produced at a high frequency from   BCR-ABL    –  transduced 
CD34  +   stem/progenitor cells independent of their apparent 
prior lineage commitment status caused by modulation of 
P210  BCR-ABL   activity (  25  ). Interestingly, we also observed that 
overexpression of   Ahi-1   in pro  –  B BaF3 cells altered their 
  diff  erentiation pattern in vivo (  Fig. 1 C  ), suggesting that 
modulation of   Ahi-1/AHI-1   expression alters progenitor cell 
diff  erentiation, including lineage switching, as previous re-
ports have suggested for other oncogenes (  25, 27  –  30  ). Third, 
a regulatory role of   Ahi-1   in   BCR-ABL    –  mediated transforma-
tion is evident as coexpression of   Ahi-1   in   BCR-ABL    –  inducible 
cells can reverse growth defi  ciencies induced by down-regu-
lation of   BCR-ABL  . This biological eff  ect is associated with 
sustained phosphorylation of BCR-ABL and enhanced activ-
ities of JAK2  –  STAT5. Finally, an AHI-1  –  BCR-ABL  –  -JAK2 
interaction complex has been identifi  ed in human CML cells. 
This complex mediates sensitivity/resistance of primitive CML 
stem/progenitor cells to TKIs, as demonstrated by either co-
expression or inhibition of   Ahi-1/AHI-1   expression in   BCR-
ABL  +     CML cells with a resulting modulation of CML cell 
sensitivity to these inhibitors. Collectively, these fi  ndings pro-
vide strong evidence of the importance of persistent deregu-
lated expression of   Ahi-1/AHI-1   to the sustained in vitro and 
in vivo transforming activities associated with CML and in 
the modulation of   BCR-ABL  -mediated malignant transfor-
mation and response of CML stem/progenitor cells to TKIs. 
This research has further identifi  ed   Ahi-1/AHI-1   as a novel 
modulator of   BCR-ABL   that is specifi  cally involved in the 
JAK2  –  STAT5 pathway. 
  Identifi  cation of an AHI-1  –  BCR-ABL  –  JAK2 interaction 
complex raises many interesting questions about the nature of 
the interaction, how it is regulated, and how it contributes to 
malignant transformation, altered BCR-ABL signaling, and 
IM response/resistance of CML stem/progenitor cells. Par-
ticularly notable is the observation that coexpression of   Ahi-1   
in   BCR-ABL    –  inducible cells can rescue GF-independent cell 
growth that is inhibited by down-regulation of   BCR-ABL  . 
Interestingly, this renewed GF independence with introduc-
tion of   Ahi-1   appears to be regulated by sustained phosphory-
lation of BCR-ABL, rather than its continual expression, as 
these eff  ects were observed in cotransduced cells where   BCR-
ABL   expression was inducibly suppressed in vitro (  Fig. 7 B  ). 
These results suggest that physical interaction between Ahi-1 
and BCR-ABL may stabilize a protein  –  protein interaction 
complex that enables constitutively active BCR-ABL tyro-
sine kinase activity and further alters specifi  c downstream 
BCR-ABL signaling pathways that deregulate cellular prolif-
eration and apoptosis control (  Fig. 9 B  ). This is further sup-
ported by identifi  cation of JAK2 as an associated protein in 
this interaction complex and observation of enhanced activity 
of the JAK2  –  STAT5 pathway in   BCR-ABL    –  inducible cells 
with cotransduction of   Ahi-1   in the presence of GF stimu-
lation with IL-3 (  Fig. 8  ). Interestingly, all these fi  ndings can 
be replicated signifi  cantly in a human CML cell line system 
in which changes in AHI-1 expression are found to modulate 
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Angeles, CA) through an EcoRI site. To generate human AHI-1 lentiviral 
vector, plasmid containing full-length   AHI-1   cDNA (AL136797, obtained 
from Resource Center Primary Database, Berlin, Germany) was subcloned 
into the EF1     -IRES-YFP lentiviral vector (with substitution of eGFP with 
YFP from an EF1     -IRES-eGFP lentiviral vector; P. Leboulch, Massachu-
setts Institute of Technology, Boston, MA) between AscI and PacI sites. To 
generate the AHI sh4 lentiviral construct, the H1 promoter-driven small 
hairpin against human   AHI-1   was released from a modifi  ed pSUPER AHI 
sh4 construct (  23  ) and inserted into an EF1     -IRES-YFP lentiviral vector. 
A similar subcloning procedure was performed to insert only the H1 promoter 
into the BamHI site of the EF1     -IRES-YFP lentiviral vector as control. 
All constructs were verifi  ed by restriction enzyme digestion analysis and 
DNA sequencing. 
  Lentiviral production was performed after a previously described proce-
dure (  47  ). The titers of these concentrated viruses were measured with HeLa 
cells as     1   ×   10  8   infectious U/ml for the BCR-ABL virus and 2   ×   10  8   infec-
tious U/ml for control, AHI sh4, and AHI-1 viruses. Helper-free retrovirus 
was obtained by transfecting ecotropic Phoenix packaging cells (  48  ) cultured 
in DMEM plus 10% fetal calf serum using the calcium-phosphate precipita-
tion method, as previously described (  46  ). 
  Human primary cells and FACS sorting.     Peripheral blood was obtained 
from 23 CML patients who had elevated white blood cell counts (105   ×   10  9   
cells/liter to 420   ×   10  9   cells/liter) and had not been treated with any inhibi-
tors, 10 of whom subsequently developed IM resistance. CB cells were ob-
tained from mothers undergoing cesarean delivery of healthy, full-term 
infants. In all cases, informed consent was obtained, and the procedures used, 
including the Declaration of Helsinki protocol, were approved by the Re-
search Ethics Board of the University of British Columbia (Vancouver). 
  Lin        CD34  +   CB cells from six individuals were isolated using the Easy-
Sep cell separation kit (Stem Cell Technologies) according to the manufac-
turer  ’  s instruction. The purity of the enriched cells was measured by FACS 
as   >  95%. FACS isolation of BaF3 cells, Sca-1  +  lin         mouse BM cells, and 
K562 cells transduced with GFP, YFP, or GFP and YFP using a FACStar 
Plus or FACSVantage (BD Biosciences) was previously described (  46  ). 
  Transduction of murine and human hematopoetic cells.     BM cells 
from 6  –  10-wk-old C57BL/6 mice were harvested 4 d after injection of 
150 mg/kg 5-FU. Low-density cells were isolated and cultured for 48 h in 
serum-free medium (SFM) supplemented with BIT (StemCell Technologies), 
to which 100 ng/ml mouse Steel Factor (SF; STEMCELL Technologies), 
10 ng/ml mouse IL-3 (StemCell Technologies), and 10 ng/ml human IL-6 
(Cangene) were also added. The BM cells, as well as IL-3  –  dependent BaF3 
cells, were then collected and resuspended at 5   ×   10  5   cells/ml in VCS di-
luted 1:3 in DMEM containing 15% FCS, protamine sulfate (5   μ  g/ml), and 
SF, IL-3, and IL-6 at the same concentrations as described above. BaF3 cells 
were cultured with IL-3 only. The cells were then transferred to Petri dishes 
that had been precoated with fi  bronectin (Sigma-Aldrich) and preloaded 
with virus as previously described (  46  ). 
  CD34  +   CB cells were prestimulated with a cocktail of cytokines and 
transduced with virus as previously described (  25  ).   BCR-ABL    –  transduced 
cells were sorted for GFP  +   cells after 3 d of culture and sorted GFP  +  BCR-
ABL  +   cells were retransduced with either control or AHI/sh4 virus. Cells 
transduced with only control or AHI/sh4 were cultured for 6 d before 
FACS sorting. The GFP  +  YFP  +   cells (BCR-ABL  +  AHI-1/sh4  +  ) were FACS-
sorted after 3 d of expansion. Lin        CD34  +   CML cells were prestimulated and 
transduced with either control or AHI/sh4 virus in a similar manner to that 
described for CB cells. After 3  –  4 d of expansion, YFP  +  CD34  +   cells were 
FACS sorted. 
  Cell culture.     FACS-sorted cells were cultured in SFM with or without 
GFs. At various time points, viable cell numbers were determined by hemo-
cytometer counts of trypan blue-excluding cells. For single cells sorting, 
YFP  +    –  transduced K562 cells were sorted into the wells of a 96 well plate by 
FACS. Subsequent clone formation (presence of   ≥  2 refractile cells) and clone 
physical interaction between Ahi-1/AHI-1 and BCR-ABL 
is revealed based on their molecular structures (  20, 43  ), which 
are compatible with specifi  c protein  –  protein interactions. Ahi-1 
may interact with BCR-ABL through its SH3 domain or its 
SH3 binding sites (i.e., the SH3 domain of one protein inter-
acting with the SH3 binding sites of the other) or through the 
SH2 domain of BCR-ABL if Ahi-1 is tyrosine phosphory-
lated (Ahi-1 contains two potential tyrosine phosphorylation 
sites). In addition, Ahi-1 may bind to a SH2-containing pro-
tein that is a substrate of BCR-ABL, thus forming a complex, 
as it is known that BCR-ABL is extensively tyrosine-phos-
phorylated, providing numerous, potential docking sites for 
SH2 domain-containing proteins (  44  ). Moreover, Ahi-1 may 
interact with multiple domains of BCR-ABL, as demonstrated 
by other BCR-ABL  –  interacting proteins (  45  ). Although more 
detailed structural mapping will be required to defi  ne specifi  c 
protein  –  protein interactions between Ahi-1 and BCR-ABL, 
in association with JAK2, our fi  ndings that coexpression of 
  Ahi-1   in   BCR-ABL    –  transduced cells can completely rescue 
IM-induced suppression of cell growth in the presence of IL-3 
suggests that Ahi-1 may not be a direct substrate of the BCR-
ABL tyrosine kinase, but rather a modular protein that forms 
a stable protein interaction complex with other tyrosine phos-
phorylated proteins to mediate IL-3  –  dependent BCR-ABL 
and JAK2  –  STAT5 activities. In addition, this protein interac-
tion complex seems to be disrupted by suppression of tyrosine 
phosphorylation of BCR-ABL by IM. Studies are underway 
to defi  ne how AHI-1 specifi  cally interacts with BCR-ABL 
and JAK2. It was interesting to note that enhanced phosphory-
lation of Src was observed in   Ahi-1   coexpressed   BCR-ABL    –
  inducible cells in the presence of IL-3 (  Fig. 8  ), suggesting that 
other kinases are also activated with stimulation of IL-3 when 
BCR-ABL and AHI-1 are coexpressed. This fi  nding also ex-
plains the observation that CML progenitor cells with sup-
pression of   AHI-1   experienced greater inhibition of CFC 
generation in response to dasatinib, a more potent TKI that 
also inhibits Src activity (  14  ). 
  In conclusion, our studies demonstrate that Ahi-1/AHI-1 
is a novel BCR-ABL interacting protein that is also physically 
associated with JAK2. This AHI-1  –  BCR-ABL  –  AK2 com-
plex seems to modulate BCR-ABL  –  transforming activity and 
TKI response/resistance of CML stem/progenitor cells through 
the IL-3  –  dependent BCR-ABL and JAK2  –  STAT5 pathway. 
These results suggest that a more promising potential thera-
peutic approach would be the combined suppression of BCR-
ABL tyrosine kinase activity, Ahi-1/AHI-1 expression, and 
JAK2  –  STAT5 signaling. 
    MATERIALS AND METHODS   
  Retroviral and lentiviral vectors and virus production.     An MSCV-
Ahi-1-IRES-YFP retroviral vector was constructed by ligating a 3.5-kb 
fragment containing full-length   Ahi-1   cDNA (  20  ) to the upstream IRES of 
the MIY vector. The MSCV-BCR-ABL-IRES-GFP (  BCR-ABL  ) retroviral 
vector was constructed as previously described (  46  ). To generate a BCR-
ABL lentiviral vector, the full-length   BCR-ABL   cDNA (J. Griffi   n, Dana 
Farber Cancer Institute, Boston, MA) was cloned into the pMNDU3-pGK-
eGFP lentiviral vector (D. Kohn, University of Southern California, Los JEM VOL. 205, October 27, 2008 
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C-terminal monoclonal anti  –  Ahi-1 antibody (C-mAhi-1 M5) generated by 
a standard procedure as previously described (  50  ), and polyclonal N-terminal 
AHI-1 antibody, IMX-3395 (IMGENEX). Relative expression levels were 
normalized to expression levels of human actin (Sigma-Aldrich) after quan-
tifi  cation with ImageQuant software. The peptide competition assay was 
completed as per an online protocol (http://www.rockland-inc.com/commerce/
misc/methods) by Rockland Immunochemicals, Inc. 
  Animals.     NOD/SCID-     2m       /       mice were bred and maintained in micro-
isolator cages and provided with autoclaved food and water. Mice were 
irradiated at 8  –  10 wk of age with 350 cGy   137  Cs      -rays. Cells were injected 
into mice intravenously a few hours after they had been irradiated. Mice were 
monitored daily for signs of weight loss or lethargy. Peripheral blood was col-
lected every 1  –  2 wk, and leukocytes were analyzed by FACS as previously 
described (  46  ). For tumor formation studies, 10 million cells were injected 
subcutaneously into the left and right fl  ank of mice, and the mice were moni-
tored daily for the tumor growth. The tumor volume was calculated from the 
greatest transverse (width) and longitudinal (length) diameter of the tumor us-
ing the formula: tumor volume = length   ×   width  2  /2. All animal experiments 
were performed in the Animal Resource Centre of BC Cancer Research 
Centre, and the procedures used were approved by the Animal Care Commit-
tee of the University of British Columbia (Vancouver). 
  Statistical analysis.     Results are shown as the mean   ±   SEM of values ob-
tained in independent experiments. Diff  erences between groups were as-
sessed using the Student  ’  s   t   test for paired samples. 
  Online supplemental material.     Fig. S1 shows that overexpression of 
  Ahi-1   confers growth advantage on BaF3 cells and enhances eff  ects of   BCR-
ABL   with increased protein expression and tyrosine phosphorylation of 
p210  BCR-ABL  . Fig. S2 shows that   Ahi-1   and   BCR-ABL    –  transduced cells 
purifi  ed from BM cells of diseased mice have increased proliferative and 
antiapoptotic activities and these eff  ects can be enhanced by   BCR-ABL  . 
The online supplemental material is available at http://www.jem.org/cgi/
content/full/jem.20072316/DC1. 
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